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Abstract
Background: The purpose of the present study was to compare side-by-side the therapeutic efficacy of a 6-day
infusion of carboplatin, followed by X-irradiation with either 6 MV photons or synchrotron X-rays, tuned above the
K-edge of Pt, for treatment of F98 glioma bearing rats.
Methods: Carboplatin was administered intracerebrally (i.c.) to F98 glioma bearing rats over 6 days using AlzetTM
osmotic pumps starting 7 days after tumor implantation. Radiotherapy was delivered in a single 15 Gy fraction on
day 14 using a conventional 6 MV linear accelerator (LINAC) or 78.8 keV synchrotron X-rays.
Results: Untreated control animals had a median survival time (MeST) of 33 days. Animals that received either
carboplatin alone or irradiation alone with either 78.8 keV or 6 MV had a MeSTs 38 and 33 days, respectively.
Animals that received carboplatin in combination with X-irradiation had a MeST of > 180 days with a 55% cure rate,
irrespective of whether they were irradiated with either 78.8 KeV synchrotron X-rays or 6MV photons.
Conclusions: These studies have conclusively demonstrated the equivalency of i.c. delivery of carboplatin in
combination with X-irradiation with either 6 MV photons or synchrotron X-rays.
Keywords: F98 rat glioma, Carboplatin, Osmotic pumps, Intracerebral delivery, Radiotherapy with 6 MV photons or
synchrotron X-rays
Background
High Z-enhanced synchrotron stereotactic radiotherapy
relies on the dose-enhancement obtained when tumors,
previously filled with a high-Z elements, are irradiated
with medium energy x-rays (50–100 keV) in stereotactic
conditions. The concept comes initially from the obser-
vation in the late 70’s, of additional blood damages in
pediatric diagnostic radiology, when using contrast
agents [1]. The use of medium energy x-rays to treat
cancer could appear surprising nowadays, specially for
brain tumors, but as the photoelectric cross section
increases proportionally to Z4/E3 (where Z is the atomic
number of matter and E the energy of photons), there is
a subsequent increase of the absorbing properties
restricted to the target level, due to the release of sec-
ondary particles (photoelectrons, characteristic x-rays
and Auger electrons), which deposit most of the initial
photon energy in the close vicinity of the primary inter-
action. Photoelectric effect is the photon interaction that
deposits locally the largest part of the photon initial
energy (when compared to coherent or incoherent scat-
tering events). This leads to improved dose distributions
in comparison with conventional high energy treat-
ments. Numerous studies have been performed for
establishing that this method meets dosimetry criteria
for patients [2-8]. From 50 to 80 keV, the brain half
value layer increases from 2.93 to 3.64 cm. Although
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these values are relatively small, the dose is increased by
(i) the irradiation geometry and (ii) by the presence of
sufficient amount of high Z elements inside the tumor
volume ( 3–10 mg/mL). LINAC spectra extend from
MV to kV energies, however, the contribution of kV ra-
diation in the dose-enhancement is negligible, as shown
with Monte carlo simulations or experimentally using
gel dosimetry [2-5,9]. The use of a modified conven-
tional CT scanner, such as proposed by Norman and co-
workers [10], appeared to be the main limitation of the
technique due to (i) the beam shape (fan or cone-shaped
beam with a high aperture) which broadens the isodoses
as the beam goes through the patient; (ii) a low photon
flux and a high thermal load which impose long irra-
diation times and cooling phases; and (iii) a broad poly-
chromatic spectrum of the beam which increases the
dose to the skull and minimizes the dose enhancement
effect. For these reasons, nearly parallel intense and
tunable monochromatic beams provided by synchrotron
source appear to be a must for this radiotherapy
technique.
In a series of publications [11-14] we have reported on
the therapeutic efficacy of short-term intracerebral (i.c.)
convection enhanced delivery (CED) of either carbopla-
tin or cisplatin or alternatively prolonged intratumoral
(i.t.) infusion of carboplatin either alone or in combi-
nation with X-irradiation for the treatment of the F98
rat glioma [11-13]. Irradiations were carried out at the
European Synchrotron Radiation Facility (ESRF) using
78.8 keV synchrotron X-rays or 6 MV photons, by a
medical linear accelerator (LINAC), at the University
Hospital of Grenoble, France. Carboplatin was selected
for these studies because we previously have shown that
it was highly effective in treating F98 glioma bearing rats
[11-14]. However, platinum containing drugs have their
limitations [15-17] for the treatment of brain tumors.
These include inadequate dose-limiting toxicity and
reduced uptake by brain tumors following systemic ad-
ministration due to the blood brain barrier (BBB) [18].
Delivery of carboplatin by CED was well tolerated when
delivered i.c. to F98 glioma bearing rats [11,12,14,19-21]
and non-human primates [22] and resulted in prolonged
survival and cures of the former.
Cure rates of 20% to 55% were obtained in F98 glioma
bearing rats treated with prolonged infusions of either
carboplatin or cisplatin using Alzet osmotic pumps alone
or in combination with synchrotron X-irradiation. In
these studies, the beam energy was tuned at 78.8 keV,
which was just above the K-edge of Pt [12,23]. The first
study carried out at the ESRF with cisplatin [23],
employed synchrotron X-rays and it was hypothesized
that therapeutic efficacy was dependent upon the pro-
duction of Auger electrons and photoelectrons following
irradiation of Pt atoms with monochromatic X-rays.
Above the Pt K-edge energy (78.4 keV), extraction of
electrons from the K-shell by the photoelectric effect
results in the creation of vacancies. The resulting gaps
are filled successively by radiative (96%) and non-
radiative (4%) transitions from outer shells, thereby
resulting in the release of several low energy photons
and electrons. If the Pt atoms are located near or within
DNA, the emitted low energy electrons can be highly
destructive for DNA and lethal to tumor cells [24], even
with small concentrations of Pt. We further hypothe-
sized that drugs such as cisplatin or carboplatin were
ideal candidates for this approach, since they had two
advantages: first, they were DNA alkylating agents [25]
and second, they were efficient carriers of Pt, which has
a high Z number. The photoelectric cross-section of Pt
at 78.8 keV is 2860 barns/atom, 4.8 times greater than at
78.0 keV. Therefore, if therapeutic efficacy were related
to the emission of Auger electrons and photoelectrons
from the Pt atoms, a greater therapeutic gain should
have been observed with X-irradiation above rather than
below the Pt K-edge. Furthermore, and most impor-
tantly, almost no enhancement should be observed with
6 MV photons. This is because the Pt photoelectric
cross is < 1 barn/atom above 1 MeV (i.e. >2860 × less
than the Pt cross section above its K-edge), which is not
significantly different from that of water. The Compton
interaction process is dominant in this energy range and
does not induce local energy deposition, contrary to the
photoelectric effect. However, our studies carried out
over the past 4 years have called this interpretation into
question. The best survival data and cure rate (55%) ever
reported with F98 glioma model were obtained by
combining i.c. administration of carboplatin by means of
Alzet osmotic pumps followed by synchrotron
X-irradiation tuned at 78.8 keV. Therefore, it was im-
portant to carry out another study under similar condi-
tions with 6 MV X-rays using a LINAC instead of
synchrotron radiation to demonstrate that this effect
was independent of the X-ray source. In the present
study we have shown the equivalency of synchrotron
X-rays [11,26] and 6 MV photons in combination with
prolonged i.c. administration of carboplatin to produce
prolonged survivals and cures of F98 glioma bearing rats.
Methods
All operative procedures related to animal care strictly
conformed to the Guidelines of the French Government
(licenses #380324 and #A3818510002). The protocol was
approved by the Grenoble Institute of Neurosciences
Ethical Committee (H. Elleaume, PhD, permit #381026).
Experiments were performed under anesthesia, and every
effort was made to minimize the number of animals used
and to alleviate pain and suffering during the experimental
procedures.
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Tumor model
F98 rat glioma cells (American Type Culture Collection
#CRL-2397) were cultured in Dulbecco’s modified eagle’s
medium (DMEM, Invitrogen, France), supplemented
with 10% fetal bovine serum and 1% penicillin/strepto-
mycin. For tumor cell implantation, male Fischer rats
(Charles River Laboratory, L’Abresles, France), weighing
260–310 g, were anesthetized with isoflurane, followed
by an i.p. injection of ketamine (60 mg/kg body weight
(b.w.) and xylazine, 7 mg/kg (b.w.). The animals’ eyes
were coated with an ocular lubricant prior to surgery to
prevent the development of keratitis. The rats were
placed in a stereotactic headframe (David Kopf Instru-
ments, Tujunga, California) and a Hamilton syringe
(#701 N 10μL) was mounted on it and this was attached
to a syringe pump to control the injection rate. A skin
incision was made, the scalp was reflected and a burr
hole was drilled 3.5 mm to the right of the bregma. A
4 μL suspension of 1000 F98 glioma cells in serum-free
DMEM was injected stereotactically into the right
caudate nucleus of syngeneic Fischer rats using a syringe
pump (KDS310; Geneq, Inc., Montréal, Quebec,
Canada). The cells were injected over 8 min via a 26
gauge needle, which was inserted to a depth of 7 mm
from the skull surface and then withdrawing it to the
target depth of 6.5 mm. After tumor cell implantation,
the needle was left in place for 2 min and then slowly
withdrawn. The burr hole in the calvarium was sealed
with bone wax, and the operative field was cleansed with
povidone iodine before closure of the scalp incision by
sutures.
Intracerebral delivery of carboplatin and experimental
plan
Carboplatin (M.W=371.25 Da, Faulding Pharmaceuti-
cals, Asnières, France) was diluted in 5% dextrose to
obtain a final concentration of 0.5 mg/mL. ALZET os-
motic pumps (model #2001, Charles Rivers Laboratories,
L’Abresles, France) and brain infusion kits (Bilaney,
Dusseldorf, Germany) were assembled and filled with
carboplatin. The pumps were stored in the dark in a
sterile solution of 0.9% saline at 37°C for 24 h prior to
their use. Seven days after tumor cell implantation the
animals were anesthetized and the scalp incision was re-
opened. The bone wax was removed with a needle, and
the infusion cannula was introduced to a depth of
6.5 mm through the hole made at the time of tumor cell
implantation. The brain infusion kit was fixed in place
with surgical glue, and the pump was implanted in a
subcutaneous pocket in the midscapular region, with a
sufficient amount of catheter tubing to permit free mo-
tion of the animal’s head and neck. The pumps were left
in place from days 7 to 13, during which time the ani-
mals received an infusion of 144 μL of carboplatin
(72 μg, 194 nmol), delivered at a flow rate of 1 μL/h over
6 days, after which the pumps were removed.
The rats, were stratified into four groups and treated
as follows: Group 1, Untreated controls; Group 2,
Received a 6 days infusion of carboplatin (72 μg/144 μL)
beginning on day 7 following tumor implantation; Group
3, Received a single 15 Gy dose of 6 MV X-rays on day
14; Group 4, Received a 6 days infusion of carboplatin,
beginning on day 7 following tumor implantation in
combination with a single 15 Gy dose of 6 MV X-rays
administered on day 14. We have compared the survival
times of these animals with the experimental groups
irradiated with synchrotron X-rays tuned at 78.8 keV, as
reported in detail in our previous report [12].
Irradiation with 6 MV photons
Irradiations were performed at the University Hospital
of Grenoble using a 6 MV LINAC (SLi, Elekta Oncology
Systems, Ltd., West Sussex, UK). Rats were placed in a
polystyrene box and were irradiated, two at a time. The
head of each animal was aligned in the middle of an
8 × 4 cm2 aperture, defined by the beam collimator, and
only the right cerebral hemisphere was irradiated. A wax
block was positioned between the rats’ heads and a
0.5 cm tissue equivalent bolus was placed on top to en-
sure full build up of the dose at the skin surface. A dose
of 15 Gy was prescribed at a 1.5 cm depth and delivered
at a dose rate of 200 cGy/min (treatment planning sys-
tem: Dosigray, DosiSoft, Cachan, France). After irradia-
tions were completed, the animals were transferred to
the Animal Care Facility at the ESRF. These irradiation
parameters were chosen to be as close as possible to the
Stereotactic synchrotron radiotherapy carried out at the
European Synchrotron Radiation Facility (ESRF), which
was previously described [12].
Tumor imaging
To confirm the presence of tumor, contrast-enhanced
imaging was performed after radiotherapy using a con-
ventional CT scanner (Siemens Somatom Plus 4 Volume
Zoom scanner, Siemens Medical Systems, Iselin, NJ,
USA). All of the animals received an intravenous (i.v.)
injection of 1.5 mL of IomeronW (350 mg/mL of iodine),
followed by 0.5 mL of a saline solution (NaCl 0.9%) via
the tail vein 10 minutes before computed tomography.
Four animals showed no evidence of tumor at this time
and they were excluded from the therapy studies.
Statistical methods
Kaplan-Meier survival plots were compared with the
log-rank test (JMP, SAS Institute Grégy sur-Yerres,
France). The log-rank test statistic compares estimates
of the hazard functions of the two groups at each
observed event time. It is constructed by computing the
Bobyk et al. Journal of Experimental & Clinical Cancer Research 2012, 31:78 Page 3 of 7
http://www.jeccr.com/content/31/1/78
observed and expected number of events in one of the
groups at each observed event time and then adding
these to obtain an overall summary across all time
points where there is an event. The rats’survival were
considered as significantly different when p < 0.05.
Results
Therapeutic response following i.c. of carboplatin in
combination with 6 MV X-irradiation
Survival data are summarized in Table 1 and Kaplan-
Meier survival plots are shown in Figure 1. The survival
plots of all treatment groups were significantly different
from those of untreated controls (p < 0.02). Untreated rats
had a mean survival time (MST) of 32± 2 d compared
with 40± 3 d for 6 MV X-irradiated animals. Rats that had
received carboplatin alone had a median survival time
(MeST) of 52 d and a censored MST of 71± 7 d, with 1
rat surviving more than 180 d, at which time the study
was terminated. Animals that had received carboplatin,
followed by X-irradiation with 6 MV photons, had a MST
of > 126± 8 d and a MeST of > 180 d, with 6 of 11 rats
(55%) alive at the end of the study. This was significantly
different from irradiated animals (p <0.01) or those that
had received carboplatin alone (p= 0.07).
Rats that received 6 MV photon irradiation alone or in
combination with i.c. carboplatin were compared with
animals that received synchrotron irradiation (data taken
from our previous study [12]) (Figure 2). Although we
could not repeat the synchrotron study due to an inabil-
ity to schedule beam time, all the control groups
(radiation alone, carboplatin alone and untreated groups)
had equivalent survival times. Both radiation sources, 6
MV photons and synchrotron irradiation, resulted in
equivalent survival data with p = 0.66 for the “irradiated
only” groups and p = 0.88 for the “chemo-radiotherapy”
groups. Similarly, equivalent survival data (p = 0.52) were
observed in both experiments for those animals that
received carboplatin alone (data not shown).
Discussion
In the present study we have demonstrated that equiva-
lent survival data were obtained in F98 glioma bearing
rats that had been treated with the combination of i.c.
infusion of carboplatin in combination with radiation
therapy using either 6 MV photons from a LINAC or a
monoenergetic beam of 78.8 keV X-rays from a synchro-
tron. Bernardt et al. have described the influence of
relaxations of atoms attached to DNA on radiation-
induced cellular DNA damage by low energy photons
using Monte Carlo track structure calculations [24].
They found that the number of inner shell relaxations
produced by photon irradiation generally was small in
comparison to the total number of double strand breaks
(DSBs) generated by the radiation itself, when the num-
ber of high Z atoms introduced by Pt containing cyto-
toxic drugs was small and compatible with cell survival
studies.
Using atomic absorption spectroscopy, Guarnieri et al.
and Kahn et al. have mapped the distribution of platinum
after i.c. infusion of carboplatin with ALZET pumps into
F98 glioma-bearing rats, with delivery parameters similar
to those that we used. Platinum concentrations were
maximal in brain sections corresponding to the infusion
site, with diminished amounts (5 to 1 μg/g tissue) in sec-
tions that were 3 mm from the point of infusion [27,28].
The importance of the DNA damage is dependent on the
number of Pt atoms intercalated with DNA molecules. At
the molecular level, a larger number of DSBs were
detected when cells were pretreated with cisplatin and
subsequently irradiated with synchrotron X-rays above the
Pt K-edge, compared to those below the K-edge [23,29].
Three times more DSBs were detected when human
SQ20B squamous carcinoma cells pretreated with 30 μM
cisplatin (3 ×× 108 atoms of Pt atoms per cell) for 6 h [29],
and 1.3 times more DSBs with the same treatment of F98
cells [23]. However, no such an enhancement was
observed (even at the molecular level) with the much
Table 1 Survival times of F98 glioma-bearing rats after prolonged infusion of carboplatin with or without 6 MV
X-irradiation from a LINAC source
Group Treatment a N Survival time (days) b % increased life span
Range Mean± SE Median Mean Median
Carboplatin 7 25-180 (1)b 71 ± 7 c 52 122 c 58
Carboplatin + 6MV 11 18-180 (6)b 126 ± 8 c >180 c 294c >445 c
X-irradiation
6MV X-irradiation 7 33-62 40 ± 3 38 25 15
Untreated controls 5 26-35 32 ± 2 33 - -
a Stereotactic intracerebral implantation of 103 F98 glioma cells was carried out on d 0. Carboplatin (72 μg or 194 nmol) was administered over d 7–13 by means
of Alzet osmotic pumps at a flow rate of 1 μL/h after which the pumps were removed.
b Day 180 was the endpoint of the experiment. Rats still alive at this time were euthanized. The number in parenthesis indicates the number of rats surviving for
more than 180 days (censored data).
c Mean, median, or % increased life span were based on censored data.
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lower Pt concentrations that would not have been tumori-
cidal, when the SQ20B cells were pretreated with 3 μM
cisplatin (4 × 106 Pt atoms per cell) for 6 h [29]. In our
studies, i.t. injection of cisplatin (3 μg in 5 μl), followed
24 h later by 15 Gy of X-irradiation, also produced similar
long-term survival of F98 glioma bearing rats, irrespective
of whether the synchrotron X-rays had energies below or
above the Pt K-edge [23]. Comparable long term cure
rates (17% and 18%) also were observed when the animals
were irradiated with 78.8 keV synchrotron X-rays or 6 MV
photons after cisplatin (6 μg in 20 μl) was administered i.c.
by CED [13]. Overall, the present data and those previ-
ously reported [11-13,23,29] are in good agreement with
Bernhardt et al’s. predictions [24]. They strongly suggest
that the therapeutic gain obtained by the direct i.c. admin-
istration of Pt compounds, followed by X-ray irradiation,
was not due to the production of Auger electrons and
photoelectrons emitted from the Pt atoms, but rather
Figure 1 Kaplan-Meier survival plots for glioma-bearing rats after chemoradiotherapy. The origin of the x-axis corresponds to tumor
implantation. Group 1: untreated (×); Group 2: Carboplatin alone (◆); Group 3: 6 MV X-irradiation alone (▲); Group 4: Carboplatin in combination
with 6 MV X-irradiation (■).
Figure 2 Kaplan-Meier survival plots for glioma-bearing rats after chemoradiotherapy using either 6MV or 78.8 keV X-rays. The origin
of the x-axis corresponds to tumor implantation. Group 3: 6 MV X-irradiation alone (▲); Group 4: Carboplatin in combination with 6 MV
X-irradiation (■). The empty symbols correspond to the experiments carried out at the European Synchrotron Radiation Facility in our previous
study at 78.8 keV [12]. 78.8 keV synchrotron irradiation alone (Δ); Carboplatin in combination with 78.8 keV synchrotron irradiation (□).
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involved other mechanisms. Only molecular studies per-
formed using extremely high Pt concentrations, which
were not attainable in vivo, demonstrated energy depend-
ence. However, this is not an adequate explanation for the
in vivo therapeutic efficacy of the combination of Pt based
chemotherapy with X-irradiation. In order for synchrotron
radiation therapy to be successful, a sufficient, but not
lethal, concentration of high Z number atoms must be
incorporated into or localized nearby tumor cells, to pro-
duce enough photoelectrons or Auger electrons. Other
elements, such as iodine, in the form of contrast agents, or
iodo-deoxyuridine (IUdR), gold, platinum or gadolinium
nanoparticles are under investigations as radiation sensiti-
zers for synchrotron stereotactic radiotherapy [30-35]. In a
recent review, Kobayashi et al. [36] discussed the enhance-
ment of radiobiological effects by heavy elements, in par-
ticular gold and platinum. Auger enhancing phenomena
to electron and Hadron therapy is also suggested which
broadens furthermore their therapeutic applications.
In another study [37] we have used the same chemo-
therapy protocol, but a different irradiation scheme: the
dose was delivered in three fractions of 5 Gy using 6
MV photons and the whole brain was irradiated, begin-
ning on the day after drug administration, using the
same Alzet osmotic pumps. The results are very consis-
tent with the data presented here, the chemotherapy
groups had the comparable survival rates (MST of 77
d ± 23.0 and 71 d± 7 and 16%, 14% long term survival
rates, respectively). Rats bearing tumors, treated with
carboplatin and X-irradiation had MST and (MeST) of
111.8 d (78 d), with 40% surviving more than 180 d
(i.e. cured), compared to 77.2 d (59 d) for pump delivery
of carboplatin alone and 31.8 d (32 d) for X-irradiated
alone. There was no microscopic evidence of residual
tumor in the brains of all long-term survivors. The
biologically equivalent dose-fraction (BED) can be calcu-
lated using the classic linear quadratic equation [38,39]:
BED ¼ n:d½1þ d:ðα=βÞ1 ð1Þ
where n is the number of fractions, d is the dose per
fraction in Gy, and α and β are two variables that indi-
cate the sensitivity of tumor or normal tissue to changes
in dose fractionation. The α/β ratio is usually taken to
be 10 for tumor and early-reacting tissues and 3 for late-
reacting tissues like brain. The biologically effective dose
(BED) for 15 Gy, delivered in a single fraction, using the
α/β ratios indicated above, is 37.5 Gy in acute and tumor
effects and 90 Gy in late effects (37). In comparison, the
BEDs for 15 Gy delivered in three fractions of 5 Gy each
are largely lower: 22.5 and 40.0 Gy, for tumor and nor-
mal brain, respectively. The dose per fraction should be
8 Gy, for obtaining BEDs in a three fractions regimen
equivalent to those of 15 Gy delivered in a single
fraction [11]. The enhanced survival results obtained
using a single fraction of 15 Gy, using either 6 MV
X-rays (this study) or synchrotron radiation [12], in
comparison with 15 Gy delivered in 3 fractions [37] is in
good agreement with the calculated equivalent BEDS of
these irradiation schemes.
Conclusions
The present study firmly establishes the equivalency of
i.c. administration of carboplatin either by infusion via
osmotic pumps or CED with irradiation with 6 MV
X-rays and synchrotron X-rays. Since medical LINACs
are widely available worldwide, this could provide the op-
portunity to clinically evaluate this combination therapy
at multiple centers. Intracerebral CED of carboplatin in
patients with recurrent glioblastomas (GBM) will be
evaluated in a soon to be initiated Phase I at The Ohio
State University. If successful, this could lead to a Phase
II clinical trial evaluating the combination of i.c. of car-
boplatin and radiation therapy to treat patients with re-
current GBMs, for whom unfortunately there are
presently no good therapeutic options.
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